Type 1 Diabetes
A Study of LY900014 in Participants With Type 1 Diabetes Mellitus
The purpose of this study is to compare LY900014 with insulin lispro (Humalog) in participants with type 1 diabetes. There are 2 parts to this study. In Part A, the study treatment will be given by injection just under the skin (subcutaneously). In Part B, the study treatment will be given by an insulin pump.
The results of this study are not yet available.
Your participation could last about 5 weeks and include up to 4 visits to the study center in each of the 2 parts of the study.
Here you can find out a bit more about the requirements for volunteers who took part in this study
Participants must have been diagnosed with Type 1 Diabetes Mellitus (T1DM) for at least 1 year
Participants must have a glycated hemoglobin (hemoglobin A1c) <10.0%
Participants must not be receiving any oral or injectable medication intended to treat diabetes other than insulin in the 12 months prior to screening
Participants must not have had more than one episode of severe low blood sugar requiring emergency treatment in the last 6 months
Participants must not have clinically significant blood, kidney, heart, liver, or gastrointestinal disease; cancer; a certain type of disease of the retina in the eye; uncontrolled celiac disease; uncontrolled thyroid disease; or adrenal insufficiency